Joseph J. Ferra Jr. - 16 Sep 2023 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Role: CHIEF EXECUTIVE OFFICER, Director
Signature: /s/ Robert Yang, Attorney-in-Fact
Issuer symbol: ELEV
Transactions as of: 16 Sep 2023
Net transactions value: -$3,475
Form type: 4
Filing time: 19 Sep 2023, 16:15:17 UTC
Previous filing: 14 Jul 2023
Next filing: 19 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ELEV	Common Stock	Options Exercise		+12,562	+20%		74,874	16 Sep 2023	Direct	F1
transaction	ELEV	Common Stock	Tax liability	$3,475	-4,773	-6.4%	$0.7280	70,101	16 Sep 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELEV	Restricted Stock Unit	Options Exercise	$0	-12,562	-12%	$0.000000	87,934	16 Sep 2023	Common Stock	12,562		Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2	25% of the RSUs vested on June 16, 2022, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F3	The RSUs do not expire; they either vest or are canceled prior to the vesting date.